Anxo Pharmaceutical Co., Ltd. (TPEX:6677)
Taiwan · Delayed Price · Currency is TWD 19.80
-0.05 (-0.25%)
Jan 22, 2026, 2:03 PM CST
Anxo Pharmaceutical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -42.34 | -57.21 | 21.86 | -12.56 | 19.23 | 31.4 | Upgrade |
Depreciation & Amortization | 75.08 | 75.63 | 73.56 | 73.41 | 73.98 | 79.31 | Upgrade |
Other Amortization | 1.16 | 1.08 | 1 | 0.8 | 0.4 | 1.7 | Upgrade |
Loss (Gain) From Sale of Assets | 0.35 | - | -0.01 | -0.47 | 0.08 | -1.33 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | - | - | -0.06 | - | Upgrade |
Stock-Based Compensation | 1.88 | 3.85 | 5.31 | 4.74 | 0.75 | - | Upgrade |
Provision & Write-off of Bad Debts | 0.93 | 0.15 | 0.16 | 0.27 | -0.25 | 0.14 | Upgrade |
Other Operating Activities | -14.42 | -15.4 | 3.54 | -2.02 | 5.67 | 16.11 | Upgrade |
Change in Accounts Receivable | 59.14 | 32.25 | -11.03 | -32.48 | -13.38 | -9.75 | Upgrade |
Change in Inventory | 25.93 | 21.45 | -40.76 | -4.22 | 28.15 | -56.49 | Upgrade |
Change in Accounts Payable | -51.64 | 1.61 | -19.84 | 15.6 | 2.01 | -14.43 | Upgrade |
Change in Unearned Revenue | -17.94 | 3.11 | -7.79 | 17.83 | 0.79 | -24.78 | Upgrade |
Change in Other Net Operating Assets | 27.72 | 45.46 | -28.65 | 10.35 | -39 | 38.01 | Upgrade |
Operating Cash Flow | 65.84 | 111.97 | -2.66 | 71.27 | 78.35 | 59.88 | Upgrade |
Operating Cash Flow Growth | 74.58% | - | - | -9.04% | 30.86% | -7.13% | Upgrade |
Capital Expenditures | -37.16 | -42.34 | -57.83 | -14.59 | -34.85 | -15.98 | Upgrade |
Sale of Property, Plant & Equipment | - | - | 3.35 | 0.47 | - | 1.33 | Upgrade |
Sale (Purchase) of Intangibles | -14.19 | -18.25 | -0.21 | -2.03 | -2.83 | - | Upgrade |
Investment in Securities | 17.01 | 75.26 | -125.03 | - | - | - | Upgrade |
Other Investing Activities | 20.81 | 20.59 | 0.48 | -6.26 | 0.32 | 2.76 | Upgrade |
Investing Cash Flow | -13.53 | 35.26 | -179.24 | -22.41 | -37.36 | -11.89 | Upgrade |
Short-Term Debt Issued | - | 645 | 809 | 709.38 | 590.45 | 653.33 | Upgrade |
Long-Term Debt Issued | - | - | - | 6.51 | 26 | 4.48 | Upgrade |
Total Debt Issued | 450 | 645 | 809 | 715.89 | 616.45 | 657.81 | Upgrade |
Short-Term Debt Repaid | - | -655 | -850.38 | -668 | -575.08 | -719.7 | Upgrade |
Long-Term Debt Repaid | - | -53.6 | -60.11 | -69.01 | -76.62 | -41.19 | Upgrade |
Total Debt Repaid | -476.18 | -708.6 | -910.49 | -737.01 | -651.7 | -760.89 | Upgrade |
Net Debt Issued (Repaid) | -26.18 | -63.6 | -101.49 | -21.12 | -35.25 | -103.08 | Upgrade |
Issuance of Common Stock | 3.54 | 2.64 | 337.5 | - | - | 95.53 | Upgrade |
Common Dividends Paid | -22.25 | -22.25 | - | - | - | -11.47 | Upgrade |
Other Financing Activities | -0.68 | -0.53 | - | -0.6 | 0.68 | 1.16 | Upgrade |
Financing Cash Flow | -45.58 | -83.75 | 236.01 | -21.72 | -34.57 | -17.86 | Upgrade |
Net Cash Flow | 6.74 | 63.48 | 54.11 | 27.14 | 6.42 | 30.13 | Upgrade |
Free Cash Flow | 28.68 | 69.63 | -60.48 | 56.68 | 43.51 | 43.9 | Upgrade |
Free Cash Flow Growth | - | - | - | 30.27% | -0.90% | 6.07% | Upgrade |
Free Cash Flow Margin | 3.25% | 7.78% | -6.44% | 6.54% | 5.28% | 5.07% | Upgrade |
Free Cash Flow Per Share | 0.51 | 1.25 | -1.17 | 1.18 | 0.90 | 0.91 | Upgrade |
Cash Interest Paid | 16.69 | 16.79 | 18.25 | 15.05 | 12.77 | 14.83 | Upgrade |
Cash Income Tax Paid | 3.41 | 11.38 | 11.71 | 9.64 | -0.58 | 0.75 | Upgrade |
Levered Free Cash Flow | 1.61 | 76.1 | -50.15 | 62.13 | 43.95 | 47.94 | Upgrade |
Unlevered Free Cash Flow | 11.95 | 86.52 | -38.85 | 71.62 | 51.93 | 56.81 | Upgrade |
Change in Working Capital | 43.21 | 103.88 | -108.07 | 7.09 | -21.45 | -67.45 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.